Outlook Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 18, 2022 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic...
Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2022 and Provides Corporate Update
May 13, 2022 08:05 ET
|
Outlook Therapeutics, Inc.
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) submitted to U.S. Food and Drug Administration (FDA); PDUFA date expected to be announced in June 2022Advancing ONS-5010...
Outlook Therapeutics to Participate in Retina World Congress 2022
May 10, 2022 08:35 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic...
Outlook Therapeutics to Participate at the Virtual Investor 2022 CEO Spotlight
May 09, 2022 08:35 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic...
BioLexis Reorganization Results in GMS Holdings as Largest Shareholder in Outlook Therapeutics
April 22, 2022 08:05 ET
|
Outlook Therapeutics, Inc.
SINGAPORE and ISELIN, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first...
Outlook Therapeutics to Present at Wet AMD and DME Drug Development Summit
April 05, 2022 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., April 05, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD
March 31, 2022 08:05 ET
|
Outlook Therapeutics, Inc.
ONS-5010 / LYTENAVA™ (bevacizumab-vikg), if approved, expected to receive 12 years of marketing exclusivity ISELIN, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq:...
Outlook Therapeutics Bolsters Commercialization Expertise with Appointment of Alicia Tozier as Senior Vice President of Marketing and Market Access
March 03, 2022 08:05 ET
|
Outlook Therapeutics, Inc.
Ms. Tozier has held commercial leadership positions across the full product lifecycle and exceeded goals for 14 launches across 70-plus global markets, with deep experience in ophthalmology and...
Outlook Therapeutics to Present at the RANZCO 52nd Annual Scientific Congress
February 24, 2022 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2022 and Provides Corporate Update
February 14, 2022 08:05 ET
|
Outlook Therapeutics, Inc.
Outlook Therapeutics remains on track to submit new U.S. FDA Biologics License Application (BLA) for first ophthalmic formulation of bevacizumab Commercial launch planning underway Financed through...